Donor Funding Drives $15M Initiative Supporting 62 Researchers Focused on Alzheimer’s, Macular Degeneration, and Glaucoma
The BrightFocus Foundation has announced a major new investment of $15.2 million in research grants aimed at advancing scientific discovery in three of the most challenging and prevalent age-related diseases: Alzheimer’s disease, macular degeneration, and glaucoma. The funding underscores the organization’s ongoing commitment to supporting innovative biomedical research, particularly at a time when uncertainty around federal research funding has created new challenges for scientists worldwide.
The newly allocated funds are distributed across BrightFocus’ three core research programs. Of the total, $8.5 million has been directed to Alzheimer’s Disease Research, $4.5 million to Macular Degeneration Research, and $2.2 million to National Glaucoma Research. In total, 62 scientists across seven countries have been selected to receive grants, reflecting a diverse and global portfolio of research efforts that span early-stage discovery through translational science.
This year’s research portfolio highlights a wide range of cutting-edge approaches designed to better understand disease mechanisms, improve early detection, and accelerate the development of new treatments. Among the most notable themes are the use of artificial intelligence to enhance diagnostic precision, the advancement of regenerative medicine techniques, and the exploration of biological differences—such as sex-based variations—that may influence disease risk and progression. These approaches represent a shift toward more personalized and technology-driven models of care in both neurology and ophthalmology.
According to BrightFocus President and CEO Stacy Pagos Haller, the organization remains steadfast in its mission despite ongoing disruptions in traditional funding channels. She noted that recent instability in federal research funding has created uncertainty across the Alzheimer scientific community, particularly for early-career investigators and those pursuing unconventional or high-risk ideas. In this context, BrightFocus’ role as an independent funding body becomes even more critical.
Haller emphasized that donor support has enabled the foundation to maintain momentum in scientific discovery and continue backing bold, innovative ideas that might otherwise struggle to secure funding. By investing in early-stage research, BrightFocus aims to generate the foundational data needed for scientists to pursue larger grants and expand their work into more advanced clinical applications.
All research proposals funded by BrightFocus undergo a rigorous evaluation process led by scientific advisory committees composed of internationally recognized experts. Alzheimer These committees assess each project’s scientific merit, innovation potential, and relevance to unmet medical needs. This peer-review process ensures that the selected studies represent some of the most promising directions in brain and eye health research.
David Holtzman, co-chair of the Alzheimer’s Disease Research Scientific Review Committee and a professor at Washington University School of Medicine, highlighted the importance of funding early-stage, high-risk research. He explained that such projects often struggle to secure federal support, yet they are essential for generating novel insights and driving breakthroughs. Holtzman also pointed out that funding challenges over the past two years have disproportionately affected emerging investigators, making philanthropic support crucial for sustaining the next generation of scientific talent.
BrightFocus’ long-standing strategy has been to invest in experimental and innovative ideas that have the potential to transform understanding of disease biology. Over the years, research supported by the foundation has contributed to several important advances now widely used in clinical practice. These include the development of more accurate blood-based biomarkers for detecting Alzheimer’s disease, as well as the creation of optical coherence tomography (OCT), a now-standard imaging technology used to diagnose and monitor eye diseases such as glaucoma and macular degeneration. Additionally, BrightFocus-funded work has contributed to the development of artificial intelligence models capable of detecting Alzheimer’s disease through retinal imaging.
The Alzheimer’s Disease Research program, which received the largest portion of this year’s funding, addresses a condition affecting more than 7 million Americans aged 65 and older. Alzheimer’s disease is a progressive neurodegenerative disorder and the leading cause of dementia, yet it still lacks a definitive cure. The newly funded projects span a broad array of scientific questions, from investigating the role of misfolded proteins such as tau in brain degeneration to examining how factors like metabolism, sleep patterns, and the gut microbiome may influence disease onset and progression.
Several studies also focus on advanced technologies, including gene editing and artificial intelligence, to better map disease pathways and predict clinical outcomes. Others explore systemic contributors to Alzheimer’s, such as cardiovascular health and immune system function, reflecting a growing understanding that the disease is influenced by interactions across multiple organ systems.
The Macular Degeneration Research program targets another major public health challenge, affecting approximately 20 million adults in the United States. As the leading cause of vision loss among older adults, age-related macular degeneration (AMD) can significantly impact quality of life. The funded projects aim to develop new therapeutic strategies for both dry and wet forms of AMD, improve diagnostic capabilities, and better understand the biological processes driving retinal degeneration.
Research in this area includes efforts to promote the survival of cone photoreceptor cells, which are critical for central vision, as well as the development of novel drug delivery systems to target retinal inflammation. Alzheimer Other projects explore the relationship between systemic health factors—such as liver function and sleep patterns—and the progression of macular degeneration, offering new perspectives on disease prevention and management.
The National Glaucoma Research program focuses on a condition that affects around 4 million adults in the United States and remains a leading cause of irreversible blindness. Because glaucoma often develops without noticeable early symptoms, many individuals are diagnosed only after significant vision loss has occurred. As a result, early detection and intervention are key priorities for researchers in this field.
The newly funded glaucoma studies emphasize innovative approaches such as the use of artificial intelligence to identify individuals at high risk and detect early structural changes in the eye. Other research efforts aim to develop therapies that protect or regenerate the optic nerve, potentially restoring vision in affected patients. Scientists are also investigating the role of immune responses and neuroinflammation in disease progression, which could lead to new treatment targets.
A recurring theme across all three research programs is the integration of advanced technologies, particularly AI, into disease detection and management. These tools have the potential to revolutionize how clinicians diagnose conditions, monitor progression, and tailor treatments to individual patients. By supporting research at the intersection of biology and technology, BrightFocus is helping to accelerate the transition toward more precise and personalized healthcare.
Notably, BrightFocus operates entirely through philanthropic support, receiving no government funding. Its research programs are sustained by contributions from individual donors, as well as grants from corporations and private foundations. This funding model allows the organization to remain flexible and responsive, directing resources toward emerging scientific opportunities that may not yet be prioritized by larger funding agencies.
Looking ahead, BrightFocus plans to make additional details about the newly funded projects available later this year, following the completion of formal agreements with participating institutions and researchers. The foundation has also opened applications for its 2027 grant cycle, encouraging scientists with innovative ideas to apply and contribute to the ongoing effort to combat neurodegenerative and vision-related diseases.
In announcing this latest round of funding, BrightFocus reaffirmed its commitment to driving progress in areas of medicine where unmet needs remain significant. By supporting a diverse array of researchers and approaches, the foundation aims to accelerate the discovery of new diagnostic tools, treatments, and ultimately cures for diseases that affect millions of people worldwide.
Source Link:https://www.businesswire.com/
